Header Logo

Connection

Kathleen Moore to Adenocarcinoma, Clear Cell

This is a "connection" page, showing publications Kathleen Moore has written about Adenocarcinoma, Clear Cell.
Connection Strength

0.652
  1. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
    View in: PubMed
    Score: 0.211
  2. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
    View in: PubMed
    Score: 0.139
  3. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
    View in: PubMed
    Score: 0.126
  4. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets. Int J Gynecol Cancer. 2015 Jul; 25(6):1015-22.
    View in: PubMed
    Score: 0.121
  5. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024 07; 186:61-68.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.